| Article
It’s important to start at the beginning and screen patients for indicators that could be suggestive of abuse, misuse, diversion, and unintentional use. We can use actual validated instruments to screen for patients who may have some issues with misuse and abuse and diversion. It is an important...
| Article
Less than 10% of the analgesics in clinical trials make it past phase II studies. There are many reasons for this, including the inability of animal models to predict efficacy in humans and the placebo response with analgesic trials. This presentation will cover the preclinical models used to study...